<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Hungarian AI drug discovery company Turbine and AstraZeneca have collaborated to discover and understand drug resistance in hematological cancers. The terms and financial details of the agreement have not been disclosed.
      </p>
    </li>
    <li>
      <p>
        The partnership will leverage Turbine's Simulated Cell platform to comprehend the resistance mechanisms caused by altered protein-protein interactions in hematological cancers.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://turbine.ai/news/turbine-announces-collaboration-to-uncover-biological-mechanisms-of-drug-resistance-in-hematological-cancers/">
      Press release
    </a>
  </p>
  <p>
    <a href="https://uk.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/Turbine-Announces-Collaboration-to-Uncover-Biological-Mechanisms-of-Drug-Resistance-in-Hematological-45687195/">
      Market Screener 
    </a>
  </p>
  <p>
  </p>
</div>


AI Drug Discovery

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>

<p>Hungarian AI drug discovery firm Turbine and pharmaceutical company AstraZeneca have formed a collaboration to study drug resistance in hematological cancers. The specific terms and financial elements of the agreement have not been made public. Through this partnership, Turbine’s Simulated Cell platform will be employed to understand the resistance caused due to changes in protein-protein interactions within hematological cancers.</p>

</div>

All Updates

Turbine partners with AstraZeneca to discover drug resistance in hematological cancers

Turbine raises additional EUR 5.5 million in Series A funding

Turbine raises EUR 20 million Series A